The Handshake Valuation: Why Selling to Your Associate Is the Most Mispriced Deal in Dentistry

The most mispriced deals in dentistry are not the DSO acquisitions. They are the internal ones — priced by relationship, financed by the seller, and audited by no one.

When a practice sells to a DSO, the number gets contested. There is a Quality of Earnings team, a diligence window, a fight over every add-back. Brutal — but the number that survives has been tested.

When a practice sells to the associate who has worked chairside with the owner for six years, none of that machinery shows up. No auction. No competing bid. No forensic review. Two people who like each other agree on a number that feels fair, a lawyer papers it, and the largest financial transaction of both of their lives closes on a valuation nobody verified.

An internal transition is the sale of a practice to a buyer already inside it — an associate, a partner, occasionally a family member. It is the only deal type where both parties routinely skip the diligence a stranger would demand. That is the Handshake Valuation, and it fails in both directions: sellers under-collect on decades of enterprise value, or buyers overpay for production that walks out the door with the founder.

Two frameworks, one table

The first forensic discipline in an internal deal is knowing which valuation framework you are in. Individual buyers — associates included — do not price practices the way institutions do.

	Associate / internal buyer	DSO / private equity
Valuation basis	SDE or % of collections — commonly 60–100% of trailing 12-month collections for solo practices	Normalized EBITDA × 5–8× (add-on)
Preparation runway	12–18 months minimum	3–5 years (the Five-Year Asymmetry)
Cash at close	Constrained by bank + seller financing	Often only 40–60% of headline; remainder in earnout/rollover
Diligence	Frequently none — the core failure	QoE audit; 85% of LMM deals re-traded post-LOI (SRS Acquiom, 2025)
Who carries post-close risk	The seller, via the seller note	The seller, via earnout/escrow — but capped and negotiated

Source: Precision Dental Analytics deal reviews; collections-percentage range per prevailing individual-buyer valuation practice; DSO structure ranges per FOCUS Investment Banking and SRS Acquiom data. Never blend the SDE and EBITDA frameworks in one negotiation.

Where you land inside the 60–100% collections band is not sentiment — it is documented, owner-independent systems. On a $900,000-collections practice, the spread between 75% and 95% of collections is $180,000. SOPs, stable staffing, and a clean data chain are what move a practice to the top of that band, associate buyer or not.

The seller becomes the bank

Here is the structural feature that makes internal deals uniquely dangerous for the seller: the financing usually runs through you.

An associate three years out of school rarely writes a seven-figure check. Bank financing covers what the associate’s production history and the practice’s documented cash flow can support — and banks lend against businesses, not personalities. Whatever the bank will not cover becomes a seller note: you hand over the keys, and the practice pays you back out of its future cash flow.

Read that structure the way a forensic analyst would. Until the note is retired, you hold practice risk without practice authority. If hygiene retention slips, if case acceptance drops without your chairside presence, if two front-desk departures scramble collections for a quarter — the practice’s problem is now your balance-sheet problem, and you no longer control any of the levers. A DSO earnout at least comes with negotiated caps, defined metrics, and an escrow agreement. A handshake seller note frequently comes with optimism.

The defense is not refusing to finance — it is sizing the note against stress-tested cash flow: the practice’s documented EBITDA after replacing your production, not before it. If the deal only works when nothing goes wrong, the deal does not work.

The associate you employed is not the owner you priced

The quiet assumption in every internal transition is that the associate’s performance as an employee predicts their performance as an owner. Your own practice-management data will tell you whether that is true — before the price is set.

Pull provider-level production and ask the owner-transition questions. What share of high-value diagnosis currently routes through you? If the founder does the implant consults, the complex treatment plans, and the case-acceptance conversations, then the practice’s production engine is not transferring with the keys — the associate is buying a machine missing its motor. What is the associate’s case acceptance on their own patients, not on the overflow you triaged to them? Does hygiene re-appointment hold steady on the associate’s exam days?

This is the same personal-versus-enterprise goodwill analysis an institutional buyer would run — pointed inward. And it cuts both ways. An associate with strong independent production data deserves a valuation that respects what they are already generating; a seller whose data shows founder-concentrated production owes the buyer — and their own note exposure — a transition plan that fixes it before close.

The internal deal’s genuine advantage lives here too: goodwill transfers better to a successor patients already know. With normal attrition running 17–25% a year regardless of a sale, a familiar face at the handoff protects the patient base better than any transition letter. That advantage is real — but it is earned in the two years before close, not assumed at the closing table.

The liabilities that ride along

Internal deals inherit internal problems. The most common one is sitting in your payroll classification: if the associate buying your practice has been paid as a 1099 independent contractor, the misclassification liability — back employment taxes, penalties, successor exposure — rides straight into the transaction. It is a strange deal where the buyer inherits a liability their own employment created, but that is precisely what an unremediated 1099 arrangement produces.

The same applies to every liability class a QoE team would price: aged patient credits, undocumented add-backs, coding patterns that would not survive a compliance audit. No one is forcing the audit — which is exactly why the disciplined move is running it anyway. The buyer who skips diligence because they trust you is trusting you to have done it.

What a defensible internal transition looks like

The paradox of the internal sale: because no adversarial buyer forces the forensics, both parties have to impose the discipline themselves.

Set the price from a forensic baseline — collections integrity, normalized earnings, goodwill attribution, provider-level production — not from a number that preserves the friendship. Size the seller note from stress-tested cash flow with the associate’s production replacing yours. Fix the classification and documentation liabilities before terms, not after. Stage the goodwill transfer deliberately: introductions, shared exam days, the successor visibly running the practice while you are still in the building. And paper it like strangers would — because in five years, when the note is half-paid and hygiene margin is drifting, you will both be glad the deal was built on data instead of goodwill of the personal kind.

The handshake is how the deal should close. It is not how the deal should be priced.

---

Structuring, tax, and classification specifics vary by state and entity — confirm your deal’s mechanics with your CPA and attorney. To see the baseline a buyer (internal or institutional) would find, run the EBITDA Leakage Diagnostic or start with the valuation calculator. If your exit is more than a year out — and an internal one should be — the exit timeline lays out the full preparation clock.

About the author — James DeLuca is the founder of Precision Dental Analytics and works in clinical data forensics and M&A defense: the “Red Team” for practice owners and sell-side brokers, mathematically hardening clinical architecture before owners face due diligence — institutional or internal. He is the author of Phantom EBITDA, Spartan Leadership, The Dental Data Playbook, and Hidden Levers. Meet the team →